Swedish biotech Cereno Scientific has delivered a transformative Q3 2024, highlighted by positive phase IIa results for its lead candidate, CS1. Backed by a series of significant milestones, a strengthened focus on rare diseases and a recent SEK 250 million capital injection, Cereno is decisively advancing towards key milestones in 2025. …
